Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleeman, Nigel, Mahon, James, Nevitt, Sarah, Duarte, Rui, Boland, Angela, Kotas, Eleanor, Dundar, Yenal, McEntee, Joanne, Ahmad, Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861391/
https://www.ncbi.nlm.nih.gov/pubmed/31240690
http://dx.doi.org/10.1007/s41669-019-0138-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861391/
https://www.ncbi.nlm.nih.gov/pubmed/31240690
http://dx.doi.org/10.1007/s41669-019-0138-z

Ejemplares similares